Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration. The company's treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that's overactive in people with hereditary angioedema, causing them to experience potentially

Tag-uri: DNA